NASDAQ · MPLT
MapLight Therapeutics, Inc.
$7.72-$0.26 (-3.26%)
MapLight Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.91% below the high.
Loading market information…
AMEX · PHGE · USD
Stock price, earnings
Quote as of Sep 10, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
BiomX Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.5% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
BiomX Inc.’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of -$703.00. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow BiomX Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Operating as a holding company, BiomX Inc. is dedicated to advancing technologies within the realms of defense, security, and essential infrastructure. Its diverse array of offerings features specialized solutions like counter-unmanned aerial vehicle systems, intelligent AI-powered command-and-control, comprehensive border and perimeter protection, expansive surveillance capabilities, and aerial fire suppression tools. The firm caters to a broad spectrum of clients, encompassing national defense organizations, primary government contractors, transportation management entities, local municipalities, and key infrastructure operators. BiomX Inc. commenced operations in 2015 and maintains its principal office in Dover, Delaware.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:17 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q3 2024 | Nov 14, 2024 | -$5.89+1.83% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
5 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$7.72-$0.26 (-3.26%)
MapLight Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.91% below the high.
$11.08+$0.01 (+0.09%)
ProMIS Neurosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.56% below the high.
$1.23-$0.01 (-0.81%)
Dogwood Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.54% below the high.
$2.70+$0.14 (+5.47%)
Edesa Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 86.71% below the high.
$0.03-$0.00 (-9.41%)
Adaptimmune Therapeutics plc’s quoted price sits in the lower half of its reported 52-week range, 92.73% below the high.
$0.92+$0.02 (+2.48%)
Immuron Limited’s quoted price sits in the lower half of its reported 52-week range, 56.69% below the high.
$0.30-$0.06 (-16.34%)
Traws Pharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.68% below the high.
$0.12$0.00 (0.0%)
OSR Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 87.17% below the high.
